Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03456271
Other study ID # 2017-NFMDXK-001
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date July 1, 2017
Est. completion date December 31, 2021

Study information

Verified date January 2021
Source Zhujiang Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The objective of this study is to find out the biochemical markers which have independent predictive value of fragility fractures risk with Type 2 diabetes in Guangzhou community and evaluate bone strength better and increase the ability of recognizing fracture risk through following-up visits the bone metabolism index like esRAGE-to-pentosidine ratio of the petients with type 2 diabetes and osteoporosis,compared with the classical fracture risk assessment instrument.


Recruitment information / eligibility

Status Terminated
Enrollment 99
Est. completion date December 31, 2021
Est. primary completion date November 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - (1) aged 18-65 years; (2) patients were diagnosed with type 2 diabetes based on the definition of diabetes of WHO in 1999. Exclusion Criteria: - 1. type 1 diabetes and other specific types of diabetes; 2. diabetes related acute complications like diabetic ketoacidosis and hyperglycemic hyperosmolar status. 3. had used drugs that is known to have effect on bone(like active vitamin D, bisphosphonate, calcitonin, estrogen receptor modulators, estrogen, thiazolidinediones); 4. suffer from diseases that is known to have effect on bone (hyperthyroidism, hypothyroidism, hyperparathyroidism, hypoparathyroidism,cushing syndrome,chronic renal failure,renal tubular acidosis,osteoporosis after gastrectomy,osteoporosis caused by liver disease,rheumatoid disease,osteoporosis induced by gastrointestinal absorption dysfunction); 5. disuse osteoporosis; 6. cannot be exposure to sunlight due to skin diseases; 7. use glucocorticoids for over 3 months.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Baiyun Community Taihe Town Guangzhou Guangdong
China Guangzhou No.12 People's Hospital Guangzhou Guangdong
China Haizhu Changgang Community Guangzhou Guangdong
China Tianhe Community Guangzhou Guangdong
China Zhujiang Hospital Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary fracture the participants happen to fracture 3 years